#USA #Tacoma #Revalesio #RNS60 #World Stroke Congress

Revalesio's Groundbreaking Presentation at World Stroke Congress 2025

In an exciting development for the medical community, Revalesio, a clinical-stage pharmaceutical leader, is set to present critical data from its Phase 2 RESCUE trial at the upcoming World Stroke Congress (WSC) 2025 in Barcelona, Spain. This presentation promises to shed light on RNS60, an investigational drug designed to provide neuroprotective benefits for patients suffering from acute ischemic strokes.

Background on RNS60 and the RESCUE Trial

The RESCUE clinical trial is significant as it was a multi-center, randomized, double-blind, placebo-controlled study assessing the safety and efficacy of RNS60 in patients eligible for Endovascular Thrombectomy (EVT). The trial primarily focuses on protecting brain tissue and promoting recovery in acute ischemic stroke patients.

Originally designed to be conducted with patients enrolled within 12 hours of symptom onset, the results of the RESCUE trial have shown that RNS60 may significantly enhance recovery outcomes when used in conjunction with EVT methods. The hope is to address a critical need, as stroke remains one of the leading causes of long-term disabilities globally.

Bert van den Bergh, the Executive Chairman of Revalesio, highlighted the dire implications of stroke, stating, "Despite advancements in stroke care, over 50% of individuals who suffer large vessel strokes are left with disabilities. Our presentation at WSC reinforces the potential of RNS60 as a vital treatment option."

Presentation Details

The highlighting session, titled The Pipeline of Acute Stroke Treatment and Prevention, will be presented by Dr. Gregory W. Albers, a key figure in vascular neurology. Here are the session specifics:

• - Date: Thursday, October 23, 2025
• - Time: 17:17 – 17:34 local time
• - Location: Room 113

Dr. Albers aims to articulate the implications of the RNS60 findings, contributing to a broader conversation on stroke treatment and prevention strategies.

What is RNS60?

RNS60 is an innovative, proprietary formulation of oxygen-enriched saline that goes beyond traditional treatments. Characterized by its cytoprotective, anti-inflammatory, and mitochondrial support mechanisms, it aims to provide adjunctive therapy for ischemic stroke patients. Moreover, it is also being explored for its potential benefits in other neurological diseases such as ALS and Alzheimer's disease.

Following positive results from the Phase 2 study, Revalesio is poised to begin a Phase 3 trial for RNS60 targeting acute ischemic stroke. The FDA has granted it Fast Track designation, emphasizing its significance as a potential breakthrough in stroke management.

Conclusion

As the date for the WSC draws near, there is palpable excitement within the medical field about Revalesio’s findings on RNS60. By providing potential new pathways for treatment, the company not only aims to alleviate the burden of stroke but also to change the narrative surrounding neurological care. All eyes will be on Revalesio's presentation as they unveil their preliminary findings, which may very well shape the future of stroke therapy.

Stay tuned for updates following the World Stroke Congress, where we will share further insights on the reception and implications of these promising findings.